Surrozen, Inc./DE (SRZN) stock
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$29.98−2.34 (-7.24%)
Close on Nov 17, 2026Market cap $352.37MP/E –Yield –
Surrozen cash
Cash and short-term investments held at the end of each period.
Surrozen's cash was $102.04M at Jun 30, 2026. For fiscal 2025 it was $89.25M, up 153.2% from the year before. The highest annual figure on record is $123.50M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.25M | +153.2% |
| FY2024 | Dec 31, 2024 | $35.25M | -4.0% |
| FY2023 | Dec 31, 2023 | $36.73M | -51.5% |
| FY2022 | Dec 31, 2022 | $75.80M | -38.6% |
| FY2021 | Dec 31, 2021 | $123.50M | +149.1% |
| FY2020 | Dec 31, 2020 | $49.59M | +68.0% |
| FY2019 | Dec 31, 2019 | $29.51M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $102.04M | +12.9% |
| Q1 FY2026 | Mar 31, 2026 | $106.91M | +5.2% |
| Q4 FY2025 | Dec 31, 2025 | $89.25M | +153.2% |
| Q3 FY2025 | Sep 30, 2025 | $81.34M | +162.3% |
| Q2 FY2025 | Jun 30, 2025 | $90.39M | +139.3% |
| Q1 FY2025 | Mar 31, 2025 | $101.65M | +176.7% |
| Q4 FY2024 | Dec 31, 2024 | $35.25M | -18.8% |
| Q3 FY2024 | Sep 30, 2024 | $31.01M | -41.9% |
| Q2 FY2024 | Jun 30, 2024 | $37.77M | -38.8% |
| Q4 FY2023 | Dec 31, 2023 | $36.73M | -51.5% |
| Q3 FY2023 | Sep 30, 2023 | $43.40M | -44.6% |
| Q2 FY2023 | Jun 30, 2023 | $53.40M | -42.4% |
| Q1 FY2023 | Mar 31, 2023 | $61.70M | -33.3% |
| Q4 FY2022 | Dec 31, 2022 | $75.80M | -38.6% |
| Q3 FY2022 | Sep 30, 2022 | $78.40M | -28.8% |
| Q2 FY2022 | Jun 30, 2022 | $92.70M | +391.8% |
| Q1 FY2022 | Mar 31, 2022 | $92.51M | +295.3% |
| Q4 FY2021 | Dec 31, 2021 | $123.50M | +149.1% |
| Q3 FY2021 | Sep 30, 2021 | $110.17M | +87.0% |
| Q2 FY2021 | Jun 30, 2021 | $18.85M | -36.1% |
| Q1 FY2021 | Mar 31, 2021 | $23.40M | – |
| Q4 FY2020 | Dec 31, 2020 | $49.59M | – |
| Q3 FY2020 | Sep 30, 2020 | $58.92M | – |
| Q4 FY2019 | Dec 31, 2019 | $29.51M | – |
See a number that looks wrong?